Cagrilintide and semaglutide are paired because they are not redundant: amylin signals through calcitonin receptor–RAMP complexes, GLP-1 signals through its own class-B receptor, and the two converge on partly shared hindbrain circuitry without competing for the same binding site. That is the mechanistic argument behind the combination usually referred to as CagriSema, and it is also the reason the pairing is interesting as a research model rather than simply as a stronger version of one drug.
Amylin: the second beta-cell hormone
Amylin (islet amyloid polypeptide) is a 37-residue hormone co-secreted with insulin from pancreatic beta cells in roughly a 1:100 molar ratio. Its physiology is distinct from insulin's: it slows gastric emptying, suppresses glucagon secretion after a meal, and promotes satiation through the area postrema, a circumventricular region outside the blood–brain barrier. Native human amylin is notoriously aggregation-prone — it forms the amyloid deposits found in islets in type 2 diabetes — which is why every therapeutic amylin analog is a re-engineered sequence rather than the native peptide.
Pramlintide, the first amylin analog to reach the clinic, solved aggregation by substituting proline residues taken from the rat sequence, but it has a short half-life. Cagrilintide is the long-acting answer: an acylated analog with a fatty-acid side chain for albumin binding, catalogued at CAS 1415456-99-3 and a molecular weight of 4,409.07 Da. It acts at the amylin receptor complexes AMY1–AMY3, formed when the calcitonin receptor associates with receptor activity-modifying proteins, and it retains activity at the calcitonin receptor itself. The full structural walkthrough is in what is cagrilintide, and the term is defined at amylin.
Why pair it with a GLP-1 analog
The two hormones are complementary at three levels.
| Cagrilintide | Semaglutide | |
|---|---|---|
| Hormone family | Amylin / calcitonin | Incretin (GLP-1) |
| Receptor | AMY1–AMY3 (CTR + RAMP1–3), calcitonin receptor | GLP-1 receptor |
| Molecular weight | 4,409.07 Da | 4,113.58 Da |
| CAS | 1415456-99-3 | 910463-68-2 |
| Primary reported actions | Gastric emptying, satiation via area postrema, glucagon suppression | Glucose-dependent insulin secretion, satiation via hypothalamic and hindbrain circuits |
| Research vial sizes | 5 mg, 10 mg | 5–50 mg |
First, receptor non-overlap means neither molecule occludes the other. Second, the downstream circuits differ enough that additive rather than merely redundant signalling is plausible — amylin's area postrema route and GLP-1's broader central and peripheral distribution are not the same map. Third, and least discussed, amylin analogs appear in the literature to influence body composition and gastric handling in ways that partly offset the tolerability ceiling of pushing a single incretin harder. The direct receptor-level comparison lives in cagrilintide vs semaglutide.
What the trial record reported
The combination moved quickly through the phases. Early-phase and phase-2 work reported that the two components produced greater mean weight reduction together than either alone at comparable durations, which is the result that justified a phase-3 programme. The REDEFINE phase-3 trials then reported topline results in obesity and in type 2 diabetes populations across 68 weeks, with the obesity trial reporting mean reductions in the low-to-mid twenties as a percentage of baseline body weight and the diabetes trial reporting a substantially smaller figure — a pattern seen across the whole incretin class, where glycaemic populations respond less on the weight endpoint than non-diabetic populations.
Two caveats belong in any honest summary. Topline percentages have varied depending on whether they are reported under a treatment-policy estimand (everyone, regardless of adherence) or an efficacy estimand (those who stayed on treatment), and the gap between those two numbers has been a live discussion point for this programme specifically. And the combination has never been shown, in a published head-to-head, to beat a triple agonist. Comparative context sits in the retatrutide 2026 update.
Fixed-ratio blends versus separate vials in research
For laboratory work the practical question is formulation. A co-formulated research vial such as semaglutide + cagrilintide supplies both peptides in one cake at a fixed mass ratio — the 10 mg presentation is 5 mg of each. That is convenient and it mirrors the clinical co-formulation, but it removes a degree of freedom: you cannot vary one component without varying the other. Separate vials of cagrilintide and semaglutide preserve that freedom at the cost of two reconstitutions and two sets of arithmetic.
Note also that mass ratio is not molar ratio. At 5 mg each, the molar quantities differ: 5 mg of cagrilintide is about 1.13 µmol while 5 mg of semaglutide is about 1.22 µmol. For receptor-occupancy reasoning the molar figure is the one that matters. The general trade-offs are covered in peptide blends vs single vials.
Reading a blend certificate of analysis also differs from reading a single-component one. A credible two-component COA resolves both peaks chromatographically, reports purity for each, and states the content ratio found by assay — not a single aggregate purity number. If a blend COA shows one peak and one percentage, it is not telling you what is in the vial. See how to read a peptide COA.
Where the amylin pairing goes next
Two directions are visible. One is pairing amylin analogs with agents beyond semaglutide — fixed-ratio research vials such as tirzepatide + cagrilintide and retatrutide + cagrilintide exist precisely to let that question be asked with a dual and a triple agonist backbone. The other is unimolecular design, where a single engineered chain carries both pharmacologies, removing the ratio question entirely.
All of these are research-grade lyophilised materials supplied for laboratory use only; none is an approved medicine, and no clinical result attaches to research vials. The broader class map is in the GLP-1 and incretin collection.